B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models

Novel therapies that effectively kill both differentiated cancer cells and cancer initiating cells (CICs), which are implicated in causing chemotherapy-resistance and disease recurrence, are needed to reduce the morbidity and mortality of ovarian cancer. These studies used monoclonal antibody (mAb) 376.96, which recognizes a B7-H3 epitope expressed on ovarian cancer cells and CICs, as a carrier molecule for targeted α-particle radioimmunotherapy (RIT) in preclinical models of human ovarian cancer.

Source: Nuclear Medicine and Biology - January 9, 2017 Category: Nuclear Medicine Authors: Benjamin B. Kasten, Rebecca C. Arend, Ashwini A. Katre, Harrison Kim, Jinda Fan, Soldano Ferrone, Kurt R. Zinn, Donald J. Buchsbaum Source Type: research